CA
MDGL icon

Commerzbank Aktiengesellschaft’s Madrigal Pharmaceuticals MDGL Stock Holding History

Commerzbank Aktiengesellschaft’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-569
Closed -$99K – 1365
2013
Q2 		$99K Buy
+569
New +$148K ﹤0.01% 1408

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Commerzbank Aktiengesellschaft's MDGL Position: Q3 2013 in Review

Commerzbank Aktiengesellschaft sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2013, closing a stake of 569 shares — an estimated $99K sold.

Commerzbank Aktiengesellschaft first reported a position in MDGL in Q2 2013 and held it in 1 quarter. The position peaked at $99K in Q2 2013. 84 funds tracked by Wall St. Rank hold MDGL as of Q3 2013.

  • Commerzbank Aktiengesellschaft reported no remaining Madrigal Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Commerzbank Aktiengesellschaft sold 569 Madrigal Pharmaceuticals shares in Q3 2013, an estimated $99K.
  • Commerzbank Aktiengesellschaft first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Commerzbank Aktiengesellschaft's Madrigal Pharmaceuticals position peaked at $99K in Q2 2013.
  • 84 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2013.

Based on Commerzbank Aktiengesellschaft's 13F filing for Q3 2013, filed 14 Nov 2013.